RxDoctor Payments Data

Eric Faile, MD

Family Medicine · Greenville, SCNPI 1942247382

Payments from drug & device makers

$15,075in general payments, 2019–2025

Across 1,070 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$995
  • Johnson & Johnson$614
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,071100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk194$2,083
AbbVie(2 entities)183$1,913
Pfizer95$1,147
AstraZeneca36$1,047
Lilly USA, LLC105$995
Johnson & Johnson35$614
Amgen(2 entities)37$546
Takeda Pharmaceuticals U.S.A., Inc.33$533
Exact Sciences17$509
Otsuka America Pharmaceutical, Inc.25$492
GSK24$411
Biohaven Pharmaceuticals, Inc.11$381
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$349
Sanofi-aventis U.S. LLC15$347
Novartis20$325
Abbott15$309
Esperion Therapeutics, Inc.17$264
Eisai Inc.26$219
Amarin Pharma, Inc.12$204
Antares Pharma, Inc.9$152
Daiichi Sankyo Inc.8$146
Lundbeck LLC9$142
Dexcom, Inc.8$136
Sumitomo Pharma America, Inc.6$127
Corium, LLC9$125
Astellas Pharma US Inc8$121
Boehringer Ingelheim8$112
Axsome Therapeutics, Inc.5$103
Biohaven Pharmaceutical Holding Company Ltd.5$86
Merck5$80
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$79
Idorsia Pharmaceuticals US Inc5$75
Nestle Healthcare Nutrition Inc.5$72
Paratek Pharmaceuticals, Inc.4$60
Supernus Pharmaceuticals, Inc.3$56
Bayer4$55
Hikma Pharmaceuticals USA3$52
Upsher-smith Laboratories LLC3$48
Adlon Therapeutics L.p.3$42
Phathom Pharmaceuticals, Inc.3$42
Sunovion Pharmaceuticals Inc.2$38
Genentech USA, Inc.3$37
Vanda Pharmaceuticals Inc.2$37
Mannkind Corporation2$35
Arbor Pharmaceuticals, Inc.2$29
E.r. Squibb & Sons, L.L.C.2$27
Tris Pharma Inc1$26
Amneal Pharmaceuticals LLC2$24
Eyevance Pharmaceuticals LLC1$24
Scilex Pharmaceuticals Inc.1$21
Phadia US Inc.1$20
Edwards Lifesciences1$20
Impel Pharmaceuticals Inc.1$19
UCB, Inc.1$15
Dynavax Technologies Corporation1$15
Therapeuticsmd, Inc.1$14
Bausch Health US, LLC1$14
Neos Therapeutics, LP1$13
Shire North American Group Inc1$13
Teva Pharmaceuticals USA, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,075 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$233,502
Medicare patients
385
Services billed
4,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$75,685
OzempicSemaglutide46$64,518
EliquisApixaban64$59,011
JardianceEmpagliflozin55$46,559
RybelsusSemaglutide27$36,897
TrulicityDulaglutide13$24,846
Tresiba Flextouch U-200Insulin Degludec21$21,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$16,532
FarxigaDapagliflozin Propanediol24$15,704
XareltoRivaroxaban14$14,444
JanuviaSitagliptin Phosphate17$13,672
Repatha SureclickEvolocumab15$12,531
Tresiba Flextouch U-100Insulin Degludec14$7,775
MyrbetriqMirabegron15$7,328
Rosuvastatin Calcium478$5,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,083$101,41573 claims
Lilly USA, LLCMounjaro, Trulicity$995$100,53191 claims
PfizerEliquis$1,147$59,01164 claims
Boehringer IngelheimJardiance$112$46,55955 claims
AstraZenecaFarxiga$1,047$15,70424 claims
Johnson & JohnsonXarelto$614$14,44414 claims
MerckJanuvia$80$13,67217 claims
Astellas Pharma US IncMyrbetriq$121$7,32815 claims
AbbVieSynthroid$1,913$3,35438 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$2,240314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →